Chuan Ning Bio (301301.SZ): The company has not yet entered into innovative drug R&D projects.

Gelonghui, June 1 — Chuan Ning Bio (301301.SZ) stated on an investor interaction platform that the company has not yet entered into innovative drug R&D projects and will continue to rely on its bio-fermentation and synthetic biology technology platforms to advance R&D efforts within its existing business areas.

Gelonghui FinanceJun 1 15:47

Chuanning Bio (301301): Profit pressure at the cyclical bottom, with expectations of recovery as 6APA prices gradually rebound.

Event: The company released its 2025 annual report and Q1 2026 earnings report. In 2025, it achieved operating revenue of 4.616 billion yuan, a year-on-year decrease of 19.83%, and net profit attributable to shareholders of 769 million yuan, a year-on-year decrease of 45.08%.

Zhongtai SecuritiesMay 8 00:00

Chuan Ning Bio: First Quarter Report for 2026

SZSIApr 23 00:00 · Announcements

Chuanning Bio (301301.SZ) released its Q1 financial results, with net profit attributable to shareholders amounting to 111 million yuan, representing a decrease of 61.58%.

Chuanning Bio (301301.SZ) released its first-quarter report for 2026. The company's operating revenue was 1.094 billion yuan, representing a year-on-year decrease of 15.61%. The net profit attributable to shareholders of the listed company amounted to 111 million yuan, marking a year-on-year decline of 61.58%. The net profit attributable to shareholders of the listed company excluding non-recurring gains and losses stood at 109 million yuan, reflecting a year-on-year drop of 61.32%. The basic earnings per share were 0.05 yuan.

Zhitong FinanceApr 22 22:56

Chuanning Bio (301301.SZ): Net profit attributable to shareholders in Q1 2026 was RMB 111 million, a year-on-year decrease of 61.58%.

Gelonghui, April 22nd – Chuan Ning Bio (301301.SZ) released its Q1 2026 report. During the reporting period, the company generated revenue of 1.094 billion yuan, representing a year-on-year decrease of 15.61%, while net profit attributable to shareholders of the listed company amounted to 111 million yuan, reflecting a year-on-year decline of 61.58%.

Gelonghui FinanceApr 22 17:22

Yili Chuanning Biotechnology Issues 200 Million Yuan in 180-Day Bonds

MT NewswiresApr 16 21:02